

HEMATOLOGY DISEASE SITE COMMITTEE

DATE -- FRIDAY APRIL 29, 2022, 11:00 AM – 1:00 PM EASTERN TIME

CO-CHAIRS : ANTHONY REIMAN, SARIT ASSOULINE
SENIOR INVESTIGATORS: LOIS SHEPHERD, ANNETTE HAY

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical trial and translational research, the disease burden associated with hematologic malignancies in Canada
- To identify clinical trial research opportunities in hematologic malignancies within the Canadian Cancer Trials Group
- To integrate current knowledge regarding therapeutics and tumour biology in hematologic malignancies in trial concept development and conduct
- To integrate and apply new clinical trial methodologies in hematologic malignancies in the Canadian Cancer Trials Group research agenda
- To provide a learning and mentoring environment supportive to new investigators

11:00 am	Introduction and Welcome	S. Assouline/ T. Reiman D. McMullen
11:05 am	Overview of Current and Planned Trials Portfolio	S. Assouline
11:15 am	Accomplishments in the past year	T. Reiman
11:25 am	Highlighting Ongoing/Soon to Open Studies	
	CLC3 MYC2 HD11 HDC1 LY17/LY18 myeloMATCH suite	V. Banerji C. Venner K. Savage/A. Prica K. Davison J. Kuruvilla L. Savoie/S. Assouline
12:20 pm	Guest Speaker - Myeloma	Dr. Noopur Raje
12:50pm	Closing Remarks	T. Reiman/S. Assouline
1:00 pm	Meeting Adjourned	